SUPERNUS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Debt Securities, Available-for-sale, Amortized Cost of $322.80 million as of 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-05-12
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $322.80M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $253.30M.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $628.46M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $624.32M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-03-31 | $322.80M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $253.30M 10-Q · filed 2022-05-12 |
| 2021-09-30 | $628.46M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $624.32M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $543.71M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $472.31M 10-K · filed 2022-04-13 |
| 2020-09-30 | $522.92M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $507.38M 10-Q · filed 2020-08-17 |
| 2020-03-31 | $710.07M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $747.60M 10-K · filed 2021-03-08 |
| 2019-09-30 | $766.57M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $757.21M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $690.85M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $586.73M 10-K · filed 2020-02-28 |
| 2018-09-30 | $621.44M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $647.25M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $223.55M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $174.24M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |